Researchers Recommend the Membrane Protein Flotillin as a Biomarker for Alzheimer’s Disease
|
By LabMedica International staff writers Posted on 12 Nov 2019 |
|
Image: Serum flotillin levels in patients with AD were lower than those in non-AD cases (Photo courtesy of Makoto Michikawa, Nagoya City University)
A team of Japanese researchers have suggested adding the protein flotillin to the arsenal of biomarkers that can be used to diagnose Alzheimer’s disease.
Flotillins are membrane proteins that form microdomains in the plasma membrane of all mammalian cell types studied to date. They span the evolutionary spectrum, with proteins related to flotillins present in bacteria, fungi, plants, and metazoans, which suggests that they perform important, and probably conserved, functions. Flotillins have been implicated in myriad processes that include endocytosis, signal transduction, and regulation of the cortical cytoskeleton, yet the molecular mechanisms that underlie flotillin function in these different cases are still poorly understood.
Investigators at Nagoya City University (Japan) had shown previously that flotillin release was reduced by amyloid beta (Abeta), a well known Alzheimer’s disease (AD) biomarker. Therefore, they designed the current study to determine whether flotillin levels would be reduced in the cerebral spinal fluid (CSF) and/or serum of patients with AD.
For this study, the investigators used western blotting to analyze flotillin levels in the CSF and serum of non-AD controls and of patients with AD and mild cognitive impairment (MCI). Flotillin levels in cerebroventricular fluid (CVF) and serum of AD, vascular dementia (VaD), and non-AD autopsy cases were also analyzed.
Results revealed that flotillin levels were significantly lower in the CSF and serum of AD patients compared with those of non-AD controls. Moreover, in patients with MCI due to AD, CSF and serum flotillin levels were significantly decreased compared with those of patients with MCI not due to AD. Flotillin levels remained unchanged in CVF and serum of autopsy cases diagnosed as VaD. Serum flotillin level was negatively associated with deposition of amyloid plaques in the brain.
The investigators postulated that these results, which were published in the October 29, 2019, online edition of the Journal of Alzheimer's Disease, demonstrated that serum flotillin level could serve as one of the blood markers for estimation of brain amyloid deposition and early diagnosis of AD.
Related Links:
Nagoya City University
Flotillins are membrane proteins that form microdomains in the plasma membrane of all mammalian cell types studied to date. They span the evolutionary spectrum, with proteins related to flotillins present in bacteria, fungi, plants, and metazoans, which suggests that they perform important, and probably conserved, functions. Flotillins have been implicated in myriad processes that include endocytosis, signal transduction, and regulation of the cortical cytoskeleton, yet the molecular mechanisms that underlie flotillin function in these different cases are still poorly understood.
Investigators at Nagoya City University (Japan) had shown previously that flotillin release was reduced by amyloid beta (Abeta), a well known Alzheimer’s disease (AD) biomarker. Therefore, they designed the current study to determine whether flotillin levels would be reduced in the cerebral spinal fluid (CSF) and/or serum of patients with AD.
For this study, the investigators used western blotting to analyze flotillin levels in the CSF and serum of non-AD controls and of patients with AD and mild cognitive impairment (MCI). Flotillin levels in cerebroventricular fluid (CVF) and serum of AD, vascular dementia (VaD), and non-AD autopsy cases were also analyzed.
Results revealed that flotillin levels were significantly lower in the CSF and serum of AD patients compared with those of non-AD controls. Moreover, in patients with MCI due to AD, CSF and serum flotillin levels were significantly decreased compared with those of patients with MCI not due to AD. Flotillin levels remained unchanged in CVF and serum of autopsy cases diagnosed as VaD. Serum flotillin level was negatively associated with deposition of amyloid plaques in the brain.
The investigators postulated that these results, which were published in the October 29, 2019, online edition of the Journal of Alzheimer's Disease, demonstrated that serum flotillin level could serve as one of the blood markers for estimation of brain amyloid deposition and early diagnosis of AD.
Related Links:
Nagoya City University
Gold Member
Troponin T QC
Troponin T Quality Control
New
Automatic Hematology Analyzer
LABAS F9000
New
Pan-Cancer Panel
TruSight Oncology 500
Latest Molecular Diagnostics News
- RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia
- New Technique for Measuring Acidic Glycan in Blood Simplifies Schizophrenia Diagnosis
- Injury Molecular Fingerprint Enables Real-Time Diagnostics for On-Site Treatment
- Blood Test Could Predict Likelihood of Breast Cancer Spreading to The Bone
- New Infectious Disease Analytics Platform Speeds Up Clinical Decision-Making at POC
- Genetic Test Could Predict Poor Outcomes in Lung Transplant Patients
- Breakthrough Blood Test Enables Early Pancreatic Cancer Detection
- Genomic Testing in NICU Reduces Missed Diagnoses
- New Genetic Test Improves Diabetes Prediction and Classification
- New Blood Test for Leukemia Risk Detection Could Replace Bone Marrow Sampling
- Blood Test Detects Preeclampsia Risk Months Before Symptoms Appear
- mNGS CSF Test Outperforms Traditional Microbiological Testing for Infectious Diseases
- Point-Of-Care Test to Transform Early-Stage Cervical Cancer Diagnosis
- PET/ctDNA-Guided Approach Helps Determine Lymphoma Treatment
- Next-Generation 'Agnostic Diagnostics' to Detect Respiratory Viruses at POC
- First-Ever Test of Cure for Chagas Disease Determines Treatment Effectiveness
Channels
Clinical Chemistry
view channel
New Clinical Chemistry Analyzer Designed to Meet Growing Demands of Modern Labs
A new clinical chemistry analyzer is designed to provide outstanding performance and maximum efficiency, without compromising affordability, to meet the growing demands of modern laboratories.... Read more
New Reference Measurement Procedure Standardizes Nucleic Acid Amplification Test Results
Nucleic acid amplification tests (NAATs) play a key role in diagnosing a wide range of infectious diseases. These tests are generally known for their high sensitivity and specificity, and they can be developed... Read more
Hematology
view channel
Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results
Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read more
Immunology
view channel
Blood Test Detects Organ Rejection in Heart Transplant Patients
Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Liquid Biopsy Approach to Transform Diagnosis, Monitoring and Treatment of Lung Cancer
Lung cancer continues to be a major contributor to cancer-related deaths globally, with its biological complexity and diverse regulatory processes making diagnosis and treatment particularly difficult.... Read more
Computational Tool Exposes Hidden Cancer DNA Changes Influencing Treatment Resistance
Structural changes in tumor DNA are among the most damaging genetic alterations in cancer, yet they often go undetected, particularly when tissue samples are degraded or of low quality. These hidden genomic... Read more
Microbiology
view channel
Viral Load Tests Can Help Predict Mpox Severity
Mpox is a viral infection that causes flu-like symptoms and a characteristic rash, which evolves significantly over time and varies between patients. The disease spreads mainly through direct contact with... Read more
Gut Microbiota Analysis Enables Early and Non-Invasive Detection of Gestational Diabetes
Gestational diabetes mellitus is a common metabolic disorder marked by abnormal glucose metabolism during pregnancy, typically emerging in the mid to late stages. It significantly heightens the risk of... Read more
Pathology
view channel
AI Performs Virtual Tissue Staining at Super-Resolution
Conventional histopathology, essential for diagnosing various diseases, typically involves chemically staining tissue samples to reveal cellular structures under a microscope. This process, known as “histochemical... Read more
AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis
Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. Often referred to as the "king" of all cancers,... Read more
Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response
Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Clinical AI Solution for Automatic Breast Cancer Grading Improves Diagnostic Accuracy
Labs that use traditional image analysis methods often suffer from bottlenecks and delays. By digitizing their pathology practices, labs can streamline their work, allowing them to take on larger caseloads... Read moreTechnology
view channel
Inexpensive DNA Coated Electrode Paves Way for Disposable Diagnostics
Many people around the world still lack access to affordable, easy-to-use diagnostics for diseases like cancer, HIV, and influenza. Conventional sensors, while accurate, often rely on expensive equipment... Read more
New Miniature Device to Transform Testing of Blood Cancer Treatments
Chimeric antigen receptor (CAR) T cell therapy has emerged as a groundbreaking treatment for blood cancers like leukemia, offering hope to patients when other treatments fail. However, despite its promise,... Read more
Industry
view channel
Lunit and Microsoft Collaborate to Advance AI-Driven Cancer Diagnosis
Lunit (Seoul, South Korea) and Microsoft (Redmond, WA, USA) have entered into a collaboration to accelerate the delivery of artificial intelligence (AI)-powered healthcare solutions. In conjunction with... Read more
